Appendix A: Administrative information.

**Trial registration number:** NL8347 (the Netherlands Trial Register)

**Protocol version:** 12

**Protocol date:** April 4th, 2022

**Trial sponsor:** Amsterdam UMC, location VU Medical Center. De Boelelaan 1117. 1081 HV Amsterdam. The Netherlands

**Funding agency:** The Netherlands Organization for Health Research and Development – Goed Gebruik geneesmiddelen (GGG) programme, grant number 848018006. The study sponsor and funder will not have any role in study design; collection, management, analysis and interpretation of data; writing of the report and the decision to submit the report for publication. The coordinating center is responsible for general coordination and daily management of the trial.

**WHO Trial Registration Data Set:**
1) Primary Registry and Trial Identifying Number: NL8347 (the Netherlands Trial Register)
2) Date of Registration in Primary Registry: February 22, 2020.
3) Secondary Identifying Numbers: n/a.
4) Source(s) of Monetary or Material Support: The Netherlands Organization for Health Research and Development (grant number 848018006).
5) Primary Sponsor: Amsterdam UMC, location VU Medical Center.
6) Secondary Sponsor(s): n/a.
7) Contact for Public Queries: Drs. D.T.P. Buis (see page 1).
8) Contact for Scientific Queries: Drs. D.T.P. Buis (see page 1).
9) Public Title: Safe shortening of antibiotic treatment duration for severe bloodstream infections with staphylococci.
10) Scientific Title: Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia.
12) Health Condition(s) or Problem(s) Studied: Staphylococcus aureus bacteremia.
13) Intervention(s): four weeks (intervention arm) or six weeks (control arm) of antibiotic treatment.
14) Key Inclusion and Exclusion Criteria:
Inclusion criteria: Patients with methicillin-sensitive complicated Staphylococcus aureus bacteremia who responded well to initial treatment.
15) Study Type: Randomized controlled open-label parallel group phase IV non-inferiority trial.
17) Sample Size: Planned to enroll 396 participants. Currently enrolled: 152 participants.
18) Recruitment Status: Recruiting.
19) Primary Outcome(s): Success of therapy at 180 days after randomization, i.e. patient alive and no evidence of microbiologically confirmed disease relapse.
22) Completion date: n/a.
23) Summary Results: n/a.
24) IPD sharing statement: Undecided.